rubicon research limited IPO
IPO Overview
Rubicon research limited IPO is a Mainboard public issue offered through a Book Building issue with a total issue size of ₹1,377.50 Cr. The IPO price band is set at ₹461 to ₹485 per share, and retail investors can apply with a minimum investment of ₹14.6K as per IPO guidelines.
The Rubicon research limited IPO opens on 9 Oct 2025 and closes on 13 Oct 2025. The IPO allotment is expected to be finalized on 14 Oct 2025, and the equity shares are proposed to be listed on BSE, NSE on 16 Oct 2025.
Investors can refer to the Rubicon research limited IPO RHP-DRHP for detailed information. The issue is managed by Axis Capital Ltd.,IIFL Capital Services Ltd.,JM Financial Ltd.,SBI Capital Markets Ltd. as the book running lead manager, while MUFG Intime India Private Limited (Link Intime) is the registrar to the IPO. Before investing, market participants often review IPO details, valuation, PE ratio, financials, and risk factors.
About Company
As of June 30, 2025, Rubicon Research had a portfolio of 72 active Abbreviated New Drug Application (ANDA) and New Drug Application (NDA) products approved by the US FDA. The company’s portfolio includes 66 commercialized products, with a US generic pharmaceutical market size of USD 2,455.7 million, of which Rubicon Research Limited contributed USD 195 million in Fiscal 2024.
As of June 30, 2025, the company has 17 new products awaiting US FDA ANDA approval and 63 products at various stages of development.
As of June 30, 2025, the company marketed over 350 SKUs to 96 customers, including three major wholesalers who, account for more than 90% of wholesale drug distribution in the US. The company also supplies group purchasing organizations (GPOs), national pharmacy chains, regional pharmacy chains, and managed care organizations.
Beyond the US market, Rubicon Research Limited, directly or through third-party distribution partners, has registered or filed 48 product applications across Australia, the United Kingdom, Singapore, Saudi Arabia, and the United Arab Emirates and expects to commence commercial activities upon approval. The company also provides contract manufacturing services to select customers in India, Australia, and New Zealand.
Rubicon Research Limited operates three manufacturing facilities in India and two US FDA inspected R&D facilities-one each in India and Canada.
Competitive strengths
Fastest-growing Indian pharmaceutical company amongst peers.
Data-driven product selection framework
Strong R&D capabilities
Robust sales and distribution capabilities in the US
Strong track record of compliance combined with expertise in cost effective manufacturing
Experienced and entrepreneurial management team
Investment Objective
Funding inorganic growth through unidentified acquisitions and other strategic initiatives and General corporate purposes